Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transient receptor potential channel 2 (TRP-2) is a member of the canonical TRP (TRPC) subfamily of ion channels, primarily recognized as a critical therapeutic target in parasitic nematodes such as Brugia malayi. It functions as a non-selective cation channel that mediates the influx of calcium and sodium ions, which is essential for parasite muscle contraction and locomotion. The anthelmintic drug diethylcarbamazine (DEC) acts as a direct agonist of TRP-2, inducing rapid spastic paralysis and facilitating the clearance of microfilariae and adult worms from the host. While TRP-2 is a functional and vital protein in many invertebrates and some mammals (where it is involved in pheromone sensing), it is a pseudogene in humans, which provides a molecular basis for the selective toxicity of DEC. In addition to its role in parasitology, TRP-2 orthologs in model organisms like C. elegans are involved in proprioception and steering during locomotion.
Agonist (Diethylcarbamazine); activates the channel to induce a rapid influx of calcium and sodium ions, leading to membrane depolarization and spastic paralysis in parasites.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transient receptor potential channel 2 (TRP-2).